In a tubule-centric view (29), the upregulation of SGLT1 and SGLT2 in PCT induced the alteration of glomerulotubular communication and hyperfiltration, explaining the renoprotective mechanisms of the novel agent SGLT2 inhibitor in DKD treatment (30–32). This evidence concerns the gene SLC5A1 and diabetic kidney disease.